

Hemophilia B (factor IXSeattle 2) due to a single nucleotide deletion in the gene for factor IX.

B G Schach, ... , S Yoshitake, E W Davie

J Clin Invest. 1987;**80**(4):1023-1028. <https://doi.org/10.1172/JCI113155>.

Research Article

To understand the molecular basis for hemophilia B in patients with little or no circulating Factor IX antigen, a patient who had less than 0.2% circulating Factor IX antigen (Factor IXSeattle 2) was selected for analysis of his Factor IX gene. Genomic DNA fragments from the abnormal gene were cloned into bacteriophage lambda vectors and recombinant phage were identified using radiolabeled genomic probes obtained from the normal Factor IX gene. The exons and flanking regions of the abnormal gene were sequenced by the dideoxy chain-termination method and this sequence was compared with that of the normal gene. Only one significant difference was observed, the deletion of a single adenine nucleotide in exon V. This resulted in a frameshift that converted an aspartic acid at position 85 in the protein to a valine and the formation of a stop signal at position 86. These data indicate that the gene for Factor IXSeattle 2 codes for an 85 residue polypeptide that terminates after the first epidermal growth factor domain. Thus, the putative Factor IXSeattle 2 polypeptide lacks the second epidermal growth factor domain, the activation peptide, and the catalytic domain present in the normal protein. This provides an explanation for the coagulation disorder in this patient and represents the first report of a single nucleotide deletion and frameshift resulting in hemophilia B.

[...]

Find the latest version:

<https://jci.me/113155/pdf>



Hemophilia B (Factor IX_{Seattle 2}) Due to a Single Nucleotide Deletion in the Gene for Factor IX

Barbara G. Schach, Shinji Yoshitake, and Earl W. Davie

Department of Biochemistry, University of Washington, Seattle, Washington 98195

Abstract

To understand the molecular basis for hemophilia B in patients with little or no circulating Factor IX antigen, a patient who had < 0.2% circulating Factor IX antigen (Factor IX_{Seattle 2}) was selected for analysis of his Factor IX gene. Genomic DNA fragments from the abnormal gene were cloned into bacteriophage λ vectors and recombinant phage were identified using radiolabeled genomic probes obtained from the normal Factor IX gene. The exons and flanking regions of the abnormal gene were sequenced by the dideoxy chain-termination method and this sequence was compared with that of the normal gene. Only one significant difference was observed, the deletion of a single adenine nucleotide in exon V. This resulted in a frameshift that converted an aspartic acid at position 85 in the protein to a valine and the formation of a stop signal at position 86. These data indicate that the gene for Factor IX_{Seattle 2} codes for an 85 residue polypeptide that terminates after the first epidermal growth factor domain. Thus, the putative Factor IX_{Seattle 2} polypeptide lacks the second epidermal growth factor domain, the activation peptide, and the catalytic domain present in the normal protein. This provides an explanation for the coagulation disorder in this patient and represents the first report of a single nucleotide deletion and frameshift resulting in hemophilia B.

Introduction

Hemophilia B (Christmas disease) is a bleeding disorder that results from a deficiency of Factor IX coagulant activity. Factor IX is one of several vitamin K-dependent proteins that are converted to serine proteases during coagulation process (1). Patients with hemophilia B can be grouped into three general categories based upon the amount of immunologically reactive Factor IX (cross-reactive material [CRM]¹) circulating in their blood (2). Individuals with normal levels of Factor IX antigen,

This article was presented in part at the plenary session of the 28th annual meeting of the American Society of Hematology, San Francisco, CA, and published as an abstract (1986. *Blood*. 68[Suppl. 1]:340).

Dr. Yoshitake's present address is Eisai Co., Ltd., Tsukuba Research Laboratories, 1-3, Tokodai 5-chome, Toyosato-machi, Tsukuba-gun, Ibaraki 300-26, Japan. Address reprint requests to Dr. E. W. Davie, Department of Biochemistry, University of Washington, Seattle, WA 98195.

Received for publication 11 March 1987 and in revised form 10 June 1987.

1. Abbreviation used in this paper: CRM, cross-reactive material.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/87/10/1023/06 \$2.00

Volume 80, October 1987, 1023-1028

but reduced Factor IX activity are designated CRM⁺, whereas those with decreased levels of antigen and a corresponding decrease in activity are designated CRM^f. Individuals with little or no factor IX antigen circulating in their blood are designated CRM⁻.

Recently, the molecular basis for hemophilia B has been determined for several CRM⁺ patients. As anticipated, an amino acid substitution in a critical region of Factor IX, such as the activation site (3) in one CRM⁺ pedigree, is sufficient for decreased Factor IX activity. Three unrelated pedigrees have amino acid substitutions in the leader sequence (4-6). Two of the reports suggest a role for the leader sequence in directing the γ -carboxylation of the amino-terminal glutamic acid residues (4, 5). An amino acid substitution near the first epidermal growth factor domain also appears to be responsible for diminished Factor IX activity in another CRM⁺ patient (7). It is not readily evident, however, how this amino acid substitution disrupts the Factor IX activity.

The molecular basis for hemophilia B has also been determined for some CRM⁻ patients. Defects thus far reported range from single nucleotide substitutions in splice junctions (8, 9) to deletions of large segments of the gene (10-12). An association between large deletions of the gene and production of antibodies directed against Factor IX has been noted by some investigators (10, 11), but not by others (12).

Cloning of the complementary DNA (cDNA) (13-15) and gene (16-18) for human Factor IX has enabled investigators to analyze the gene from patients with hemophilia B. This approach has complemented classic methods of protein analysis in CRM⁺ patients and is the only approach currently available to study CRM⁻ patients.

To better understand the molecular basis for hemophilia B in patients with little or no circulating Factor IX antigen, the gene coding for Factor IX was selected for study from a patient with virtually no detectable Factor IX protein. It was anticipated that a small genetic defect similar to those previously reported for patients with thalassemia (19) might account for the absence of circulating Factor IX. Therefore, fragments of the gene coding for the deficient protein, designated Factor IX_{Seattle 2}, were cloned and the coding regions, splice junctions, proposed promoter region, and the 3' processing region were sequenced. This led to the identification of a single adenine nucleotide deletion at nucleotide number 17,699 in exon V, which accounts for the molecular basis of hemophilia B in this patient.

Methods

Materials. The DNA restriction endonuclease EcoRI, T4 DNA ligase, and λ gtWES-EcoRI arms were purchased from Bethesda Research Laboratories, Gaithersburg, MD. M13mp18 and M13mp19 sequencing vectors and sequencing kits were purchased from New England Biolabs, Beverly, MA. [³²S]dATP α S and λ DNA in vitro packaging kits were purchased from Amersham Corp., Arlington Heights, IL. Proto-

clone GT System λ gt11 DNA and λ EMBL3 DNA were products of Promega Biotec, Madison, WI. 32 P-labeled deoxynucleotides were purchased from New England Nuclear, Boston, MA, and nitrocellulose, from Schleicher & Schuell, Inc., Keene, NH. X-ray film (XRP1 and XAR) was obtained from Eastman Kodak, Co., Rochester, NY, and synthetic DNA oligonucleotide primers specific for Factor IX were prepared by Dr. Foon Lee at the Howard Hughes Medical Institute Synthesis Facility at the University of Washington, Seattle, WA. DNA sequence analysis was performed by using the program Genepro (Riverside Scientific, Seattle, WA).

DNA preparation and analysis. Genomic DNA was prepared from the peripheral lymphocytes obtained from a patient with little or no circulating Factor IX (Factor IX_{Seattle 2}) and from two normal controls, according to established methods (20). 10 μ g of DNA from the patient and each normal control was digested with the restriction endonuclease EcoRI. The restriction fragments were separated by size on a 0.7% agarose gel in 90 mM Tris buffer, pH 8.3, containing 90 mM boric acid and 2 mM EDTA and transferred to nitrocellulose according to the method of Southern (21). The blot was probed with a nick-translated cDNA coding for Factor IX, labeled according to the method of Rigby et al. (22). Prehybridization was carried out in 50 mM Tris buffer, pH 7.0, containing 0.3 M NaCl and 100 μ g/ml salmon testes DNA (TS buffer) and 50% deionized formamide at 42°C for 5 h. Hybridization was performed in a fresh solution of TS buffer with 50% deionized formamide and 1×10^6 cpm/ml radiolabeled Factor IX cDNA. After ~ 24 h, the blot was washed at a final stringency of $0.1 \times$ standard saline citrate (SSC),² and 0.5% sodium dodecyl sulfate (SDS) at room temperature for 15 min. Excess wash solution was blotted from the nitrocellulose, and the blot was then enclosed in Saran Wrap. The blot was exposed to XRP1 x-ray film with an intensifying screen at -70°C for 4 d.

Construction of genomic libraries. Approximately 100 μ g of DNA from the patient was digested to completion with the restriction endonuclease EcoRI. The restriction fragments were separated according to size on a 0.5% agarose gel in 90 mM Tris buffer, pH 8.3, containing 90 mM boric acid and 2 mM EDTA. Gel slices containing fragments in the range of 10–15, 6.7–9.4, 5.3–7, 3.9–5, and 1.4–2 kilobase (kb) were isolated from the gel and treated, as previously described by Yoshitake et al. (16).

A separate library was constructed for each size-fractionated fragment. The mixture containing the 12.5-kb fragment coding for exon I was cloned into bacteriophage λ EMBL3 (23), as described by Yoshitake et al. (16). The mixture containing the 4.9-kb fragment coding for exons II, III, and IV and the 4.8-kb fragment coding for exon V was cloned into bacteriophage λ gt11 (24). Likewise, the mixture containing the 1.8-kb fragment coding for the 3' end of exon VIII was cloned into λ gt11. The mixtures containing the 6.8-kb fragment coding for exon VI and the 5.5-kb fragment coding for exons VII and VIII were cloned into λ gtWES (25). A typical ligation reaction was performed overnight at 15°C in 5 μ l of ligase buffer (50 mM Tris buffer, pH 7.4, 10 mM MgCl₂, 10 mM dithiothreitol, and 1 mM ATP, 50 μ g/ml bovine serum albumin [BSA]) with 0.5–1 Weiss units of T4 DNA ligase. The reaction mixture also contained a total of ~ 0.5 μ g of vector plus genomic DNA. The molar ratios of genomic to vector DNA varied between 1:1 for the 6.8-kb insert to 6:1 for the 1.8-kb fragment. Reaction conditions were optimized for each insert size and vector combination using theoretical considerations (26) and empirical adjustments. Ligations were packaged *in vitro* according to the manufacturer's instructions.

Library screening. The λ EMBL3 library was grown in *Escherichia coli* strain Q359, and the λ gt11 and λ gtWES libraries, in strain Y1090. Nick-translated genomic probes prepared from the normal Factor IX gene were used to screen the libraries. The plaque hybridization method of Benton and Davis (27) was used with the following modifications. Prehybridization was performed in $2 \times$ SSC, $2 \times$ Denhardt's (0.04% each of polyvinylpyrrolidone 360, ficoll 600, and BSA), 0.5%

SDS, 1 mM EDTA, pH 7.5, at 60°C until the nitrocellulose filters were thoroughly wet (from 15 min to 2 h). Hybridization was carried out in fresh solution containing 2×10^5 cpm/ml probe for ~ 16 –24 h. The filters were rinsed in $2 \times$ SSC, 0.5% SDS, pH 7.5, at room temperature, followed by a wash in fresh solution at 60°C for 10 min. The filters were dried, covered with Saran Wrap, and exposed to Kodak XAR film in the presence of an intensifying screen at -70°C for 5–20 h. Positive clones were plaque-purified and then amplified by the liquid culture lysis method of Silhavy et al. (28).

DNA sequencing. Restriction fragments containing exons with some flanking intron sequences were subcloned into M13 phage vectors (29, 30). Sequencing was carried out by the dideoxy chain-termination method of Sanger et al. (31), as modified for [35 S]dATP (32). Oligonucleotide primers specific for Factor IX were designed and used in sequencing several of the exons.

Results and Discussion

A Southern blot of an EcoRI restriction digest of genomic DNA from a patient with severe Factor IX deficiency (Factor IX_{Seattle 2}) was probed with a radiolabeled cDNA for Factor IX. Four bands of ~ 12.5 , 6.8, 5.5, and 4.8 kb were identified by Southern blotting and were indistinguishable from bands present in adjacent lanes from the normal controls. The origin of these bands is illustrated by the EcoRI restriction map shown in Fig. 1. Note that the 4.8-kb fragment coding for exon V cannot be distinguished from the 4.9-kb band coding for exons II, III, and IV by Southern blot analysis of a 0.7% agarose gel. These preliminary experiments indicated that essentially all of the coding regions for the normal Factor IX gene were also present in the gene from the patient with Factor IX deficiency.

A number of λ phage libraries were then constructed from the genomic DNA from the patient, as described under Methods. The number of phage screened for all library constructions is shown in Table I. Between 4×10^5 and 2.5×10^6 phage were screened for each Factor IX genomic fragment. From one to six positive clones were identified for each fragment and plaque purified, except for the library containing exon VII and the majority of exon VIII. A total of 4,162 bases of Factor IX_{Seattle 2} gene were sequenced employing the genomic inserts in the phage. This included 857 bases of DNA sequence from the exons and several hundred bases of flanking sequence for each exon.

When comparing the DNA sequence of the gene for Factor IX_{Seattle 2} with the normal Factor IX gene (16), five differences were noted. The only significant difference, however, involved the deletion of a single adenine nucleotide at position 17,699 in the gene for Factor IX_{Seattle 2} (Fig. 2). This deletion corresponds to the first base in exon V where the adenine nucleotide is part of the triplet GAT coding for aspartic acid at position 85




Figure 1. EcoRI restriction enzyme map of the gene for human Factor IX. Exons are represented by the open boxes (not to scale) and introns by the horizontal line. The exon numbers are indicated by the roman numerals. EcoRI restriction sites are indicated by the vertical lines. Bars below the gene indicate the restriction fragments that contain exons. Their approximate sizes are shown in kilobases.

2. $20 \times$ SSC contains 3 M NaCl and 0.3 M sodium citrate, pH 7.0.

Table I. Genomic Libraries from the Gene for Factor IX_{Seattle 2}

Insert size	Vector	Exons cloned	No. of phage screened	Positives obtained
<i>kb</i>				
12.5	λEMBL3	I	4.3 × 10 ⁵	1
4.9	λgt11	II, III, IV	2.3 × 10 ⁶	2
4.8	λgt11	V	6.0 × 10 ⁵	2
6.8	λgtWES	VI	4.7 × 10 ⁵	1
5.5	λgtWES	VII, 5' VIII	8.0 × 10 ⁵	0
1.8	λgt11	3' VIII	1.1 × 10 ⁶	6

in the normal protein. In the gene for Factor IX_{Seattle 2}, the deletion results in a frameshift such that a GTT codes for a valine at position 85 and the next triplet becomes TAA, which is a stop codon (Fig. 3). The deletion was verified by sequencing two independently isolated clones for exon V from a non-amplified library. Thus, it is highly unlikely that the deletion was the result of a cloning artifact in the same position in these two independent clones. Also, the deletion was demonstrated by sequencing both DNA strands in the region of the defect. The deletion of this nucleotide cannot be demonstrated by DNA restriction endonuclease digestion since it does not create or alter any known restriction site.

This single-base deletion is the first reported frameshift mutation responsible for Factor IX deficiency in a patient with hemophilia B. Similar frameshift mutations have previously been reported for β globin deficiencies in cases of β thalassemia (33–36). Probable frameshift mutations with less damaging




Figure 2. Nucleotide sequence of the coding strand of exon V in the gene for Factor IX. Sequence from the normal gene is shown on the left and that from the gene for Factor IX_{Seattle 2}, on the right. In the normal sequence, the A that is identified by the arrow and surrounded by the open box is the nucleotide that is absent in the gene for Factor IX_{Seattle 2}.




Figure 3. Effect of the single nucleotide deletion on the putative protein sequence of Factor IX_{Seattle 2}. A portion of the coding sequence for normal Factor IX with its translation into protein sequence is shown on top. Numbers above the amino acids indicate their position in the mature protein. The A nucleotide (open box) is the nucleotide that has been deleted in the gene for Factor IX_{Seattle 2}. Below the normal sequence is the corresponding sequence coding for Factor IX_{Seattle 2}. As a result of the deleted A in the codon for amino acid 85, a frameshift occurs that converts the aspartic acid at position 85 to a valine, and the valine at position 86 to a stop codon.

consequences have also been reported for other proteins, such as albumin (37).

The mechanism responsible for the nucleotide deletion in this case is not known. The deleted adenine nucleotide occurs in the first base of the seven-base tandem repeat of ATG-TAAC. There is no similarity of this sequence pattern with patterns previously associated with deletions in the DNA slippage hypothesis (38, 39) or other hypotheses (40, 41). Instead the deletion may be explained by a mechanism like dislocation mutagenesis, which is not dependent on a specific DNA sequence (42, 43). As more frameshift mutations are analyzed, it is anticipated that the mechanisms responsible for small deletions will be better understood.

The second difference between the normal and abnormal genes identified a potential FokI restriction fragment length polymorphism at position 6,843 in which the G in the normal gene has been replaced with an A in the gene for Factor IX_{Seattle 2}. This eliminates the FokI restriction site that begins at nucleotide number 6,842. Individuals possessing this FokI site would have two fragments of ~ 270 and 1,690 base pairs after digestion with FokI, whereas individuals without the site would have a single fragment of 1,960 base pairs. Since FokI cuts the gene for Factor IX frequently and only 21 bases of the cDNA would hybridize in the area of interest, genomic probes specific for this region would be better suited than cDNA probes when screening for this polymorphism. Alternatively, synthetic oligonucleotide probes designed to match the polymorphic site could be used for screening. The frequency of this polymorphism in the population is not currently known. Like other restriction fragment length polymorphisms, its usefulness may be limited because of linkage disequilibrium with other polymorphic sites already identified. This difference occurs within an intron about 1 kb downstream from the third exon and has no effect on the coding region of the gene.

The last three differences between the normal and abnormal genes were found to be errors in the sequence in the 5' flanking region of the normal gene, which was published earlier from our laboratory (16). These included the replacements of a T with an A at -2,176, -2,104, and -2,105. These errors occur over 2 kb upstream from the promoter region and have no effect on the amino acid sequence of the protein.

A comparison of the tentative structure of the normal circulating Factor IX protein with the structure predicted by the gene for Factor IX_{Seattle 2} is shown in Fig. 4. The Factor IX_{Seattle 2} protein contains the γ-carboxyglutamic acid domain, the first epidermal growth factor domain, and terminates with a valine




Figure 4. Comparison of the tentative protein structure for normal Factor IX with the structure predicted for Factor IX_{Seattle 2}. Normal Factor IX is on the left, and Factor IX_{Seattle 2} is on the right. The arrow in the normal Factor IX indicates the location of the amino acid substitution and termination point for Factor IX_{Seattle 2}.

at position 85. Thus, the Factor IX_{Seattle 2} protein is lacking the second epidermal growth factor domain, the activation peptide, and the catalytic domain.

It has not been established that this truncated protein circulates in the plasma of the Factor IX_{Seattle 2} patient. The very low level of protein (< 0.2%) detected in the plasma of the patient is at the lower limit of the sensitivity of the radioimmunoassay used to detect the Factor IX antigen (44, 45). Also, this patient is on home care therapy and the possibility of residual Factor IX from previous treatments cannot be excluded. Possible explanations for the virtually undetectable Factor IX_{Seattle 2} antigen levels include an unstable messenger RNA (mRNA) that is rapidly turned over without being translated, or an unstable protein that is not secreted or that is rapidly degraded inside the cell or in circulation. Also, rapid clearance of the truncated protein via renal filtration is a likely possibility. A processed but unstable mRNA, secondary to a frameshift mutation, has been identified in the reticulocytes of a β thalassemia patient (33).

Several potential polyadenylation signals are located downstream of the newly generated stop codon in the gene for Factor IX_{Seattle 2} at positions 18,585, 18,652, 18,717, and beyond. However, assessment of the Factor IX mRNA level in the Factor IX_{Seattle 2} patient is not feasible since it would require a liver biopsy specimen. Analysis of the patient's urine for Factor IX antigen, however, is more feasible. Bray and Thompson (46) have already identified a hemophilia B pedigree in which renal clearance of a truncated Factor IX protein, Factor IX_{Seattle 1}, resulted in very low levels of circulating Factor IX antigen.

Regardless of the mechanism behind the markedly reduced Factor IX antigen, the Factor IX_{Seattle 2} patient has a severe deficiency of Factor IX activity. The deficiency would persist even if the truncated protein specified by his gene were circulating at normal levels because the gene for Factor IX_{Seattle 2} codes for a nonfunctional protein. This protein lacks the catalytic domain and other domains that are probably essential for binding Factor IX to co-factors or substrates. The possibility that other point mutations may occur elsewhere in the gene cannot be ruled out since the whole gene was not sequenced. However, it is highly probable that the primary cause of hemophilia B in this patient is due to the deletion of a single nucleotide in exon V.

Acknowledgments

The authors thank Dr. Dominic Chung, Dr. Donald Foster, Dr. Koto Kurachi, Dr. Steven Leytus, and Dr. Arthur Thompson for helpful discussions. Also, we would like to express our gratitude to Mr. Stanley Yates for his assistance in this investigation.

This work was supported in part by research grant HL 16919 from the National Institutes of Health, and by a Judith Graham Pool Postgraduate Research Fellowship from the National Hemophilia Foundation (Dr. Schach).

References

1. Hedner, U., and E. W. Davie. 1982. Factor IX. *In* Hemostasis and Thrombosis. R. W. Colman, J. Hirsh, V. J. Marder, and E. W. Salzman, editors. J. B. Lippincott Co., Philadelphia. 29-38.
2. MacGraw, R. A., L. M. Davis, R. L. Lundblad, D. W. Stafford,

and H. R. Roberts. 1985. Structure and function of factor IX defects in hemophilia B. *Clin. Haematol.* 14:359-383.

3. Noyes, C. M., M. J. Griffith, H. R. Roberts, and R. L. Lundblad. 1983. Identification of the molecular defect in factor IX_{Chapel Hill}: substitution of histidine for arginine at position 145. *Proc. Natl. Acad. Sci. USA.* 80:4200-4202.

4. Diguil, D. L., M. J. Rabiet, B. C. Furie, H. A. Liebman, and B. Furie. 1986. Molecular basis of hemophilia B: a defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor. *Proc. Natl. Acad. Sci. USA.* 83:5803-5807.

5. Ware, J., H. Liebman, C. Kasper, J. Graham, B. C. Furie, B. Furie, and D. Stafford. 1986. Genetic characterization of a hemophilia B variant: factor IX_{San Dimas}. *Blood.* 68:343. (Abstr.)

6. Bentley, A. K., D. J. G. Rees, C. Rizza, and G. G. Brownlee. 1986. Defective propeptide processing of blood clotting factor IX caused by mutation of arginine to glutamine at position -4. *Cell.* 45:343-348.

7. Davis, L. M., R. A. MacGraw, J. L. Ware, H. R. Roberts, and D. W. Stafford. 1987. Factor IX_{Alabama}: a point mutation in a clotting protein results in hemophilia B. *Blood.* 69:140-143.

8. Rees, D. J. G., C. R. Rizza, and G. G. Brownlee. 1985. Haemophilia B caused by a point mutation in a donor splice junction of the human factor IX gene. *Nature (Lond.)* 316:643-645.

9. Brownlee, G. G. 1986. The molecular genetics of haemophilia A and B. *J. Cell Sci.* 4:445-458.

10. Giannelli, F., K. H. Choo, D. J. G. Rees, Y. Boyd, C. R. Rizza, and G. G. Brownlee. 1983. Gene deletions in patients with haemophilia B and anti-factor IX antibodies. *Nature (Lond.)* 303:181-182.

11. Peake, I. R., B. L. Furlong, and A. L. Bloom. 1984. Carrier detection by direct gene analysis in a family with haemophilia B (factor IX deficiency). *Lancet.* 1:242-243.

12. Chen, S.-H., S. Yoshitake, P. F. Chance, G. L. Bray, A. R. Thompson, C. R. Scott, and K. Kurachi. 1985. An intragenic deletion of the factor IX gene in a family with hemophilia B. *J. Clin. Invest.* 76:2161-2164.

13. Kurachi, K., and E. W. Davie. 1982. Isolation and characterization of a cDNA coding for human factor IX. *Proc. Natl. Acad. Sci. USA.* 79:6461-6464.

14. Jaye, M., H. de la Salle, F. Schamber, A. Balland, V. Kohli, A. Findeli, P. Tolstoshev, and J.-P. Lecocq. 1983. Isolation of a human anti-haemophilic factor IX cDNA clone using a unique 52-base synthetic oligonucleotide probe deduced from the amino acid sequence of bovine factor IX. *Nucleic Acids Res.* 11:2325-2335.

15. Jagadeeswaran, P., D. E. Lavelle, R. Kaul, T. Mohandas, and S. T. Warren. 1984. Isolation and characterization of human factor IX cDNA: identification of *TaqI* polymorphism and regional assignment. *Somatic Cell Mol. Genet.* 10:465-473.

16. Yoshitake, S., B. G. Schach, D. C. Foster, E. W. Davie, and K. Kurachi. 1985. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). *Biochemistry.* 24:3736-3750.

17. Anson, D. S., K. H. Choo, D. J. G. Rees, F. Giannelli, K. Gould, J. A. Huddleston, and G. G. Brownlee. 1984. The gene structure of human anti-haemophilic factor IX. *EMBO (Eur. Mol. Biol. Organ.) J.* 3:1053-1060.

18. Choo, K. H., K. G. Gould, D. J. G. Rees, and G. G. Brownlee. 1982. Molecular cloning of the gene for human anti-haemophilic factor IX. *Nature (Lond.)* 299:178-180.

19. Nienhuis, A. W., N. P. Anagnou, and T. J. Ley. 1984. Advances in thalassemia research. *Blood.* 63:738-758.

20. Bell, G. I., J. H. Karam, and W. J. Rutter. 1981. Polymorphic DNA region adjacent to the 5' end of the human insulin gene. *Proc. Natl. Acad. Sci. USA.* 78:5759-5763.

21. Southern, E. M. 1975. Detection of specific sequences among DNA fragments separated by gel electrophoresis. *J. Mol. Biol.* 98:503-517.

22. Rigby, P. W., M. Dieckmann, C. Rhodes, and P. Berg. 1977. Labeling deoxyribonucleic acid to high specific activity *in vitro* by nick translation with DNA polymerase. *J. Mol. Biol.* 113:237-251.

23. Frischauf, A.-M., H. Lehrach, A. Poustka, and N. Murray. 1983. Lambda replacement vectors carrying polylinker sequences. *J. Mol. Biol.* 170:827-842.
24. Young, R. A., and R. W. Davis. 1983. Efficient isolation of genes by using antibody probes. *Proc. Natl. Acad. Sci. USA.* 80:1194-1198.
25. Leder, P., D. Tiemeier, and L. Enquist. 1977. EK2 derivatives of bacteriophage lambda useful in the cloning of DNA from higher organisms: the λ gtWES system. *Science (Wash. DC).* 196:175-177.
26. Dugaiczky, A., H. W. Boyer, and H. M. Goodman. 1975. Ligation of *EcoRI* endonuclease-generated DNA fragments into linear and circular structures. *J. Mol. Biol.* 96:171-184.
27. Benton, W. D., and R. W. Davis. 1977. Screening λ gt recombinant clones by hybridization to single plaques *in situ*. *Science (Wash. DC).* 196:180-182.
28. Silhavy, T. J., M. L. Berman, and L. W. Enquist. 1984. Preparation of 1-liter λ lysates. In *Experiments with gene fusion*. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. 93-94, 140-141.
29. Messing, J., R. Crea, and P. H. Seeburg. 1981. A system for shotgun DNA sequencing. *Nucleic Acids Res.* 9:309-321.
30. Norrander, J., T. Kempe, and J. Messing. 1983. Construction of improved M13 vectors using oligodeoxynucleotide-directed mutagenesis. *Gene (Amst.).* 26:101-106.
31. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA.* 74:5463-5467.
32. Biggin, M. D., T. J. Gibson, and G. F. Hong. 1983. Buffer gradient gels and ^{35}S label as an aid to rapid DNA sequence determination. *Proc. Natl. Acad. Sci. USA.* 80:3963-3965.
33. Kinniburgh, A. J., L. E. Maquat, T. Schedl, E. Rachmilewitz, and J. Ross. 1982. mRNA-deficient β -thalassemia results from a single nucleotide deletion. *Nucleic Acids Res.* 10:5421-5427.
34. Kimura, A., E. Matsunaga, Y. Takihara, T. Nakamura, Y. Takagi, S.-T. Lin, and H.-T. Lee. 1982. Structural analysis of a β -thalassemia gene found in Taiwan. *J. Biol. Chem.* 258:2748-2749.
35. Kazazian, H. H., S. H. Orkin, C. D. Boehm, J. P. Sexton, and S. E. Antonarakis. 1983. β -thalassemia due to a deletion of the nucleotide which is substituted in the β^e -globin gene. *Am. J. Hum. Genet.* 35:1028-1033.
36. Chang, J. C., A. Alberti, and Y. W. Kan. 1983. A β -thalassemia lesion abolishes the same *MstII* site as the sickle mutation. *Nucleic Acids Res.* 11:7789-7794.
37. Galliano, M., L. Minchiotti, P. Iadarola, M. C. Zapponi, G. Ferri, and A. A. Castellani. 1986. Structural characterization of a chain termination mutant of human serum albumin. *J. Biol. Chem.* 261:4283-4287.
38. Streisinger, G., Y. Okada, J. Emrich, J. Newton, A. Tsugita, E. Terzaghi, and M. Inouye. 1966. Frameshift mutations and the genetic code. *Cold Spring Harbor Symp. Quant. Biol.* 31:77-84.
39. Farabaugh, P. J., U. Schmeissner, M. Hofer, and J. H. Miller. 1978. Genetic studies of the *lac* repressor VII. On the molecular nature of spontaneous hotspots in the *lacI* gene of *Escherichia coli*. *J. Mol. Biol.* 126:847-863.
40. Glickman, B. W., and L. S. Ripley. 1984. Structural intermediates of deletion mutagenesis: a role for palindromic DNA. *Proc. Natl. Acad. Sci. USA.* 81:512-516.
41. Schaaper, R. M., B. N. Danforth, and B. W. Glickman. 1986. Mechanisms of spontaneous mutagenesis: an analysis of the spectrum of spontaneous mutation in the *Escherichia coli lac I* gene. *J. Mol. Biol.* 189:273-284.
42. Kunkel, T. A. 1986. Frameshift mutagenesis by eucaryotic DNA polymerases *in vitro*. *J. Biol. Chem.* 261:13581-13587.
43. Kunkel, T. A., and S. A. Alexander. 1986. The base substitution fidelity of eucaryotic DNA polymerases. *J. Biol. Chem.* 261:160-166.
44. Thompson, A. R. 1983. Monoclonal antibody to an epitope on the heavy chain of factor IX missing in three hemophilia B patients. *Blood.* 62:1027-1034.
45. Bray, G. L., A. F. Weinmann, and A. R. Thompson. 1986. Calcium-specific immunoassays for factor IX: reduced levels of antigen in patients with vitamin K disorders. *J. Lab. Clin. Med.* 107:269-278.
46. Bray, G. L., and A. R. Thompson. 1986. Partial factor IX protein in a pedigree with hemophilia B due to a partial gene deletion. *J. Clin. Invest.* 77:1194-1200.